Proscia is at the forefront of digital pathology, offering an enterprise pathology platform known as Concentriq, which serves as a central hub for managing digital pathology data and AI applications. This platform enables anatomic pathology laboratories to achieve complete digitization, facilitating faster and more accurate diagnostic processes. By integrating real-world data and advanced AI solutions, Proscia empowers life sciences organizations to enhance their research and development efforts, driving innovation from drug discovery through to clinical trials. The platform's capabilities include optimizing image analysis workflows, improving data integrity, and enabling collaboration across teams, which collectively contribute to accelerating the delivery of life-saving therapies and diagnostics.

In addition to its core platform, Proscia leverages one of the world's largest pathology databases to provide actionable real-world data that supports scientific discovery and pharmaceutical development. This data is enriched with structured clinical and genomic information, allowing researchers to develop AI models and biomarkers that can significantly impact precision medicine. Proscia's AI solutions, including Concentriq Embeddings, facilitate the rapid development of high-performing AI algorithms, enhancing the efficiency of drug development processes. By harmonizing diverse datasets and employing advanced computational pathology techniques, Proscia is positioned to transform the landscape of drug development and improve patient outcomes.

United States

Proscia is a software company accelerating pathology's transformation toward a data-driven discipline. Our Concentriq® digital pathology platform and AI-powered computational pathology software are redefining the pathology laboratory and enhancing cancer diagnosis.

Proscia

Company Details